FY2026 EPS Estimates for Liquidia Decreased by HC Wainwright

Liquidia Corporation (NASDAQ:LQDA) – Analysts at HC Wainwright decreased their FY2026 earnings estimates for shares of Liquidia in a research note issued on Thursday, August 13th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of $3.44 for the year, down from their prior forecast of $3.97. The consensus estimate for Liquidia’s current full-year earnings is $2.57 per share. HC Wainwright also issued estimates for Liquidia’s Q4 2026 earnings at $1.18 EPS, FY2027 earnings at $6.41 EPS, FY2028 earnings at $7.39 EPS, FY2029 earnings at $9.01 EPS and FY2030 earnings at $10.08 EPS.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The company had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. During the same period in the prior year, the firm posted ($0.49) EPS. The firm’s quarterly revenue was up 1842.1% on a year-over-year basis.

Several other equities research analysts have also commented on the company. Royal Bank Of Canada set a $130.00 price target on Liquidia in a research note on Friday, July 24th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $106.00 price objective on shares of Liquidia in a research note on Thursday. Zacks Research cut Liquidia from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Friday, July 17th. Finally, Wall Street Zen downgraded Liquidia from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $98.08.

Liquidia Trading Up 4.4%

Shares of Liquidia stock opened at $77.70 on Monday. Liquidia has a 12-month low of $21.15 and a 12-month high of $93.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. The stock has a market cap of $6.95 billion, a PE ratio of 56.72 and a beta of 0.58. The company has a 50-day moving average of $78.94 and a two-hundred day moving average of $55.47.

Insider Buying and Selling

In other news, CAO Dana Boyle sold 1,600 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $87.53, for a total value of $140,048.00. Following the sale, the chief accounting officer directly owned 167,919 shares in the company, valued at $14,697,950.07. This represents a 0.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sanjeev Khindri sold 1,185 shares of the firm’s stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $71.51, for a total transaction of $84,739.35. Following the transaction, the insider directly owned 65,947 shares of the company’s stock, valued at approximately $4,715,869.97. This trade represents a 1.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 1,731,861 shares of company stock valued at $121,514,862. 25.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Liquidia

A number of large investors have recently bought and sold shares of LQDA. Covestor Ltd increased its position in Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after buying an additional 359 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Liquidia by 7.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company’s stock valued at $217,000 after acquiring an additional 422 shares in the last quarter. Quantinno Capital Management LP boosted its stake in shares of Liquidia by 3.6% during the first quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock valued at $648,000 after acquiring an additional 589 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Liquidia during the fourth quarter valued at $25,000. Finally, ProShare Advisors LLC boosted its stake in shares of Liquidia by 7.1% during the fourth quarter. ProShare Advisors LLC now owns 11,756 shares of the company’s stock valued at $405,000 after acquiring an additional 775 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).